AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
AAC Accepts, published online ahead of print on 5 May 2008
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00043-08v1
52/7/2449    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Empel, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Empel, J.
Antimicrob. Agents Chemother. doi:10.1128/AAC.00043-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Molecular survey of {beta}-lactamases conferring resistance to newer generation {beta}-lactams in Enterobacteriaceae in Polish hospitals

Joanna Empel, Anna Baraniak, Elzbieta Literacka, Agnieszka Mrówka, Janusz Fiett, Ewa Sadowy, Waleria Hryniewicz, Marek Gniadkowski*, and The Beta-PL Study Group

National Medicines Institute, 00-725 Warsaw, Poland

* To whom correspondence should be addressed. Email: gniadkow{at}cls.edu.pl.


   Abstract

The first national survey of resistance to newer generation {beta}-lactams in nosocomial populations of Enterobacteriaceae was performed in Poland. The study covered all non-repetitive enterobacterial isolates cultured from inpatients in 13 regional secondary-care hospitals from November 2003 to January 2004. Among 2,388 isolates, the predominant species was Escherichia coli (59.6%), followed by Proteus mirabilis (14.5%), and Klebsiella spp. (8.5%). The frequency of extended-spectrum {beta}-lactamases (ESBLs) was very high, with 11.1% among all isolates and 40.4% in Klebsiella pneumoniae, the latter value much exceeding that for E. coli (2.5%). The contribution of outbreak isolates was significant, resulting for example in a particularly high rate of ESBLs in Serratia marcescens (70.8%). The pool of ESBL types was totally dominated (81.7%) by CTX-M-like {beta}-lactamases, CTX-M-3 (80.6%) and CTX-M-15, followed by SHV types (17.5%; SHV-2, SHV-5, SHV-12), and sporadic TEM-like enzymes (0.7%; TEM-19, TEM-48). Acquired AmpC-type cephalosporinases were observed exclusively in P. mirabilis, accounting for 20.5% of its isolates (compared with 11.5% of ESBL producers in that species). All these enzymes were of the Citrobacter freundii origin (CMY-12, CMY-15, and a novel variant CMY-38). Four isolates of E. coli, K. pneumoniae and P. mirabilis produced class A inhibitor-resistant {beta}-lactamases (TEM-30, TEM-32, TEM-37 and SHV-49), being the first isolates of that kind identified in Poland. The survey documented both specific and more global characteristics of the epidemiology of the {beta}-lactamase-mediated resistance in enterobacteria in Polish hospitals, and demonstrated that the ESBL frequency has reached the alarming level.







Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.